Ergomed   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Guildford Surrey United Kingdom (1997)

Organization Overview

First Clinical Trial
1998
NCT00977483
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ergomed | Ergomed GmbH

Active Ingredients

Drugs in Phase 4 Trials (1)

purethal birch (1 trial)

Drugs in Phase 3 Trials (4)

Key: Ergomed (3) Acquired (1)

alm-488 (1 trial)

alpha-lipoic acid (1 trial)

house dust mite allergen (1 trial)

levofloxacin (levaquin) (1 trial)

Drugs in Phase 2 Trials (10)

Key: Ergomed (5) Acquired (5)

cysteamine (cystagon) (1 trial)

docetaxel (taxotere) (1 trial)

gs-248 (1 trial)

peprostat (2 trials)

p. pratense pollen extract (1 trial)

sepranolone (1 trial)

sevuparin (1 trial)

sodium chloride (1 trial)

tro19622 (1 trial)

trovafloxacin (trovan) (1 trial)

Drugs in Phase 1 Trials (1)

multikine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Asthma (Phase 3)

Condylomata Acuminata (Phase 1)

Conjunctivitis (Phase 2)

Diabetic Neuropathies (Phase 3)

Peripheral Nervous System Diseases (Phase 2)

Polyneuropathies (Phase 3)

Premenstrual Dysphoric Disorder (Phase 2)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Warts (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 16